 Katherine Rennie
Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hair Cells, Vestibular | 20 | 2023 | 27 | 6.050 |
Why?
| | Potassium | 10 | 2014 | 132 | 1.860 |
Why?
| | Action Potentials | 9 | 2023 | 420 | 1.810 |
Why?
| | Potassium Channels | 7 | 2016 | 123 | 1.630 |
Why?
| | Vestibule, Labyrinth | 5 | 2023 | 54 | 1.440 |
Why?
| | Gerbillinae | 17 | 2020 | 63 | 1.350 |
Why?
| | Sodium | 6 | 2020 | 200 | 1.200 |
Why?
| | Neurons, Afferent | 4 | 2023 | 89 | 1.110 |
Why?
| | Membrane Potentials | 12 | 2023 | 253 | 1.080 |
Why?
| | Ear, Inner | 2 | 2016 | 39 | 1.040 |
Why?
| | Excitatory Postsynaptic Potentials | 2 | 2017 | 105 | 0.990 |
Why?
| | Nasal Obstruction | 2 | 2023 | 27 | 0.950 |
Why?
| | Sodium Channel Blockers | 2 | 2020 | 24 | 0.850 |
Why?
| | Tetrodotoxin | 2 | 2020 | 39 | 0.850 |
Why?
| | Ion Channels | 3 | 2012 | 126 | 0.840 |
Why?
| | Patch-Clamp Techniques | 12 | 2016 | 247 | 0.820 |
Why?
| | Nasal Septum | 2 | 2023 | 17 | 0.790 |
Why?
| | Sarcopenia | 1 | 2022 | 72 | 0.780 |
Why?
| | NAV1.6 Voltage-Gated Sodium Channel | 1 | 2020 | 9 | 0.770 |
Why?
| | Vestibular Nerve | 1 | 2020 | 16 | 0.760 |
Why?
| | Nose Deformities, Acquired | 1 | 2020 | 2 | 0.740 |
Why?
| | Resistance Training | 1 | 2022 | 120 | 0.730 |
Why?
| | Rhinoplasty | 1 | 2020 | 20 | 0.720 |
Why?
| | Frailty | 1 | 2022 | 116 | 0.720 |
Why?
| | Conservative Treatment | 1 | 2020 | 31 | 0.720 |
Why?
| | Receptors, AMPA | 2 | 2017 | 125 | 0.670 |
Why?
| | Metformin | 1 | 2022 | 295 | 0.660 |
Why?
| | Presynaptic Terminals | 2 | 2011 | 58 | 0.660 |
Why?
| | Semicircular Canals | 5 | 2009 | 28 | 0.650 |
Why?
| | Potassium Channel Blockers | 5 | 2014 | 30 | 0.630 |
Why?
| | Sodium Channels | 2 | 2009 | 63 | 0.620 |
Why?
| | Hair Cells, Auditory | 5 | 2016 | 39 | 0.560 |
Why?
| | Hair Cells, Auditory, Inner | 2 | 2009 | 13 | 0.500 |
Why?
| | Neomycin | 1 | 2013 | 6 | 0.480 |
Why?
| | Gentamicins | 1 | 2013 | 42 | 0.470 |
Why?
| | Anthracenes | 3 | 2014 | 30 | 0.440 |
Why?
| | Animals | 29 | 2023 | 33381 | 0.420 |
Why?
| | Apamin | 1 | 2011 | 6 | 0.420 |
Why?
| | Small-Conductance Calcium-Activated Potassium Channels | 1 | 2011 | 8 | 0.420 |
Why?
| | Synapses | 2 | 2017 | 344 | 0.410 |
Why?
| | Hair Cells, Ampulla | 1 | 2010 | 1 | 0.380 |
Why?
| | Calcium | 5 | 2011 | 1169 | 0.340 |
Why?
| | Mechanotransduction, Cellular | 2 | 2014 | 101 | 0.340 |
Why?
| | Columbidae | 7 | 2004 | 31 | 0.330 |
Why?
| | 4-Aminopyridine | 6 | 2014 | 21 | 0.330 |
Why?
| | Cations | 2 | 2016 | 79 | 0.320 |
Why?
| | Ion Channel Gating | 2 | 2005 | 85 | 0.310 |
Why?
| | Cells, Cultured | 6 | 2017 | 4077 | 0.290 |
Why?
| | Cell Membrane | 2 | 2016 | 710 | 0.290 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1244 | 0.270 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2005 | 50 | 0.260 |
Why?
| | Anti-Bacterial Agents | 1 | 2013 | 1510 | 0.240 |
Why?
| | Physical Stimulation | 1 | 2004 | 79 | 0.240 |
Why?
| | Mammals | 2 | 2023 | 253 | 0.230 |
Why?
| | Models, Neurological | 2 | 2005 | 216 | 0.230 |
Why?
| | Electric Conductivity | 5 | 2004 | 91 | 0.200 |
Why?
| | Steroids, Fluorinated | 1 | 2020 | 1 | 0.190 |
Why?
| | Scotland | 1 | 2020 | 12 | 0.190 |
Why?
| | Wales | 1 | 2020 | 18 | 0.190 |
Why?
| | England | 1 | 2020 | 68 | 0.180 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2020 | 78 | 0.180 |
Why?
| | Administration, Intranasal | 1 | 2020 | 79 | 0.180 |
Why?
| | Double-Blind Method | 2 | 2022 | 1687 | 0.180 |
Why?
| | Electrophysiology | 5 | 2009 | 204 | 0.170 |
Why?
| | Multicenter Studies as Topic | 1 | 2020 | 253 | 0.170 |
Why?
| | Indoles | 1 | 2001 | 316 | 0.160 |
Why?
| | Female | 12 | 2023 | 61564 | 0.150 |
Why?
| | Benzothiadiazines | 1 | 2017 | 3 | 0.150 |
Why?
| | 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2017 | 11 | 0.150 |
Why?
| | Strontium | 1 | 2017 | 14 | 0.150 |
Why?
| | Endoscopy | 1 | 2020 | 272 | 0.150 |
Why?
| | Pyridines | 1 | 2001 | 440 | 0.150 |
Why?
| | Nifedipine | 1 | 2017 | 29 | 0.150 |
Why?
| | Clinical Decision-Making | 1 | 2020 | 278 | 0.150 |
Why?
| | Male | 9 | 2023 | 57801 | 0.150 |
Why?
| | Dipeptides | 1 | 2017 | 51 | 0.150 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 554 | 0.150 |
Why?
| | Quinoxalines | 1 | 2017 | 62 | 0.140 |
Why?
| | Calcium Channel Blockers | 1 | 2017 | 117 | 0.140 |
Why?
| | DNA, Mitochondrial | 2 | 2009 | 187 | 0.140 |
Why?
| | Ranidae | 1 | 2016 | 12 | 0.140 |
Why?
| | Calcium Channels, L-Type | 1 | 2017 | 110 | 0.140 |
Why?
| | Chick Embryo | 1 | 2016 | 129 | 0.140 |
Why?
| | Self Report | 1 | 2020 | 699 | 0.140 |
Why?
| | Patient Selection | 1 | 2020 | 676 | 0.140 |
Why?
| | Electrophysiological Phenomena | 1 | 2016 | 51 | 0.140 |
Why?
| | Coculture Techniques | 1 | 2016 | 208 | 0.140 |
Why?
| | Neurotransmitter Agents | 1 | 2016 | 76 | 0.130 |
Why?
| | Fishes | 1 | 2016 | 85 | 0.130 |
Why?
| | Birds | 1 | 2016 | 81 | 0.130 |
Why?
| | Acetylcholine | 1 | 2016 | 208 | 0.130 |
Why?
| | Elapid Venoms | 1 | 2014 | 16 | 0.130 |
Why?
| | Calcium Channels | 1 | 2016 | 150 | 0.130 |
Why?
| | Beta vulgaris | 1 | 2014 | 4 | 0.130 |
Why?
| | Tissue Culture Techniques | 1 | 2014 | 67 | 0.130 |
Why?
| | Nitrates | 1 | 2014 | 78 | 0.120 |
Why?
| | Phytotherapy | 1 | 2014 | 69 | 0.120 |
Why?
| | Choline | 1 | 2014 | 109 | 0.120 |
Why?
| | Carrier Proteins | 1 | 1997 | 726 | 0.120 |
Why?
| | Quality of Life | 2 | 2023 | 2366 | 0.110 |
Why?
| | Age Factors | 1 | 2020 | 2995 | 0.110 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 267 | 0.110 |
Why?
| | Saccule and Utricle | 3 | 2004 | 4 | 0.110 |
Why?
| | Cyclic GMP | 1 | 2012 | 109 | 0.110 |
Why?
| | Bee Venoms | 1 | 2011 | 8 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2674 | 0.100 |
Why?
| | Cyclic AMP | 1 | 2012 | 242 | 0.100 |
Why?
| | Cesium | 3 | 2000 | 17 | 0.100 |
Why?
| | Adenosine Triphosphate | 1 | 1993 | 439 | 0.100 |
Why?
| | Dietary Supplements | 1 | 2014 | 467 | 0.100 |
Why?
| | Nitric Oxide | 1 | 2016 | 892 | 0.090 |
Why?
| | Guinea Pigs | 3 | 1997 | 151 | 0.090 |
Why?
| | Treatment Outcome | 2 | 2023 | 9342 | 0.090 |
Why?
| | Pyrimidines | 1 | 2012 | 382 | 0.090 |
Why?
| | Animals, Newborn | 1 | 2011 | 806 | 0.090 |
Why?
| | Mitochondrial Diseases | 1 | 2009 | 79 | 0.080 |
Why?
| | Embryonic Stem Cells | 1 | 2009 | 114 | 0.080 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 336 | 0.080 |
Why?
| | Blood Pressure | 1 | 2014 | 1664 | 0.080 |
Why?
| | Humans | 7 | 2023 | 118972 | 0.070 |
Why?
| | In Vitro Techniques | 3 | 1994 | 1094 | 0.070 |
Why?
| | NADH Dehydrogenase | 1 | 2006 | 18 | 0.070 |
Why?
| | Acidosis, Lactic | 1 | 2006 | 29 | 0.070 |
Why?
| | Hypertension | 1 | 2014 | 1203 | 0.070 |
Why?
| | Point Mutation | 1 | 2006 | 228 | 0.060 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2004 | 25 | 0.060 |
Why?
| | Mice | 3 | 2016 | 15520 | 0.060 |
Why?
| | Tetraethylammonium Compounds | 2 | 1996 | 9 | 0.060 |
Why?
| | Turtles | 1 | 2004 | 11 | 0.060 |
Why?
| | State Medicine | 1 | 2023 | 21 | 0.060 |
Why?
| | Aged | 1 | 2022 | 19657 | 0.060 |
Why?
| | Mitochondria | 1 | 2009 | 786 | 0.060 |
Why?
| | Cloning, Molecular | 1 | 2004 | 546 | 0.060 |
Why?
| | Adult | 3 | 2023 | 31512 | 0.060 |
Why?
| | Steroids | 1 | 2023 | 153 | 0.060 |
Why?
| | Cell Differentiation | 1 | 2009 | 1753 | 0.050 |
Why?
| | Obesity | 1 | 2014 | 2746 | 0.050 |
Why?
| | Capsaicin | 1 | 2001 | 26 | 0.050 |
Why?
| | Neurons | 1 | 2009 | 1345 | 0.050 |
Why?
| | Rats | 1 | 2009 | 5392 | 0.050 |
Why?
| | Computer Simulation | 1 | 2005 | 922 | 0.050 |
Why?
| | Calcium Signaling | 1 | 2001 | 219 | 0.040 |
Why?
| | Cell Division | 1 | 2001 | 776 | 0.040 |
Why?
| | Aging | 1 | 2009 | 1670 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2004 | 1795 | 0.040 |
Why?
| | Cell Separation | 3 | 1997 | 296 | 0.040 |
Why?
| | Sodium-Potassium-Chloride Symporters | 1 | 1997 | 9 | 0.040 |
Why?
| | Chlorides | 1 | 1997 | 137 | 0.040 |
Why?
| | Kinetics | 2 | 1997 | 1624 | 0.040 |
Why?
| | Feeder Cells | 1 | 2016 | 1 | 0.040 |
Why?
| | Species Specificity | 2 | 1997 | 565 | 0.040 |
Why?
| | Clone Cells | 1 | 2016 | 248 | 0.030 |
Why?
| | Heterografts | 1 | 2016 | 130 | 0.030 |
Why?
| | Posture | 1 | 1996 | 158 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2004 | 2445 | 0.030 |
Why?
| | Plant Preparations | 1 | 2014 | 23 | 0.030 |
Why?
| | Plant Roots | 1 | 2014 | 39 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2016 | 443 | 0.030 |
Why?
| | Beverages | 1 | 2014 | 70 | 0.030 |
Why?
| | Barium | 1 | 1994 | 27 | 0.030 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2014 | 66 | 0.030 |
Why?
| | Fura-2 | 1 | 1993 | 21 | 0.030 |
Why?
| | Electrodes | 1 | 1994 | 89 | 0.030 |
Why?
| | Vegetables | 1 | 2014 | 133 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 965 | 0.030 |
Why?
| | Electric Stimulation | 1 | 1994 | 268 | 0.030 |
Why?
| | Tetraethylammonium | 1 | 1991 | 15 | 0.020 |
Why?
| | Cadmium | 1 | 1991 | 62 | 0.020 |
Why?
| | Hybrid Cells | 1 | 2009 | 46 | 0.020 |
Why?
| | Electron Transport | 1 | 2009 | 101 | 0.020 |
Why?
| | Neurogenesis | 1 | 2009 | 105 | 0.020 |
Why?
| | Synaptic Transmission | 1 | 2009 | 239 | 0.020 |
Why?
| | Body Mass Index | 1 | 2014 | 2092 | 0.020 |
Why?
| | Electron Transport Complex I | 1 | 2006 | 36 | 0.020 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2006 | 107 | 0.020 |
Why?
| | Aortic Coarctation | 1 | 2006 | 57 | 0.020 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2006 | 146 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2006 | 287 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2006 | 381 | 0.020 |
Why?
| | Avian Proteins | 1 | 2004 | 20 | 0.020 |
Why?
| | Cricetulus | 1 | 2004 | 98 | 0.020 |
Why?
| | CHO Cells | 1 | 2004 | 143 | 0.020 |
Why?
| | Cricetinae | 1 | 2004 | 262 | 0.020 |
Why?
| | Organ Specificity | 1 | 2004 | 278 | 0.010 |
Why?
| | Oocytes | 1 | 2004 | 190 | 0.010 |
Why?
| | Streptomycin | 1 | 2001 | 14 | 0.010 |
Why?
| | Base Sequence | 1 | 2004 | 2159 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2004 | 2071 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2009 | 4908 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2009 | 3730 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2004 | 2871 | 0.010 |
Why?
| | Cell Line | 1 | 2004 | 2707 | 0.010 |
Why?
| | Mutation | 1 | 2009 | 3457 | 0.010 |
Why?
| | RNA | 1 | 2004 | 833 | 0.010 |
Why?
| | Cochlea | 1 | 1997 | 88 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2006 | 5255 | 0.010 |
Why?
| | Middle Aged | 1 | 2014 | 27617 | 0.010 |
Why?
| | Infant | 1 | 2006 | 8293 | 0.010 |
Why?
| | Homeostasis | 1 | 1996 | 594 | 0.010 |
Why?
|
|
Rennie's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|